ID   HuCC-T1-G100
AC   CVCL_QZ45
SY   HuCCT1-G100
DR   cancercelllines; CVCL_QZ45
DR   Wikidata; Q54896727
RX   PubMed=21451941;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4071_4072insGATT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0324 ! HuCC-T1
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=21451941; DOI=10.1007/s00534-011-0376-7;
RA   Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y.,
RA   Tsuchiya T., Gotoh M.;
RT   "Gene expression analysis for predicting gemcitabine resistance in
RT   human cholangiocarcinoma.";
RL   J. Hepatobiliary Pancreat. Sci. 18:700-711(2011).
//